Ultomiris
Term · Oncology and biomedicine · MLC-T-ONC-009020
A drug used to treat adults with paroxysmal nocturnal hemoglobinuria (a rare red blood cell disorder) and adults and children aged 1 month and older with atypical hemolytic uremic syndrome (a very rare disorder in which tiny blood clots form in small blood vessels). It is also being studied in the treatment of other conditions. Ultomiris binds to an immune system protein called C5. This may help keep red blood cells from breaking down and blood clots from forming. Ultomiris is a type of monoclonal antibody. Also called ravulizumab.
| Identifier | MLC-T-ONC-009020 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | ravulizumab |
| References | NCI Dictionary of Cancer Terms |
Record as JSON
{
"id": "MLC-T-ONC-009020",
"term": "Ultomiris",
"field": "Oncology and biomedicine",
"definition": "A drug used to treat adults with paroxysmal nocturnal hemoglobinuria (a rare red blood cell disorder) and adults and children aged 1 month and older with atypical hemolytic uremic syndrome (a very rare disorder in which tiny blood clots form in small blood vessels). It is also being studied in the treatment of other conditions. Ultomiris binds to an immune system protein called C5. This may help keep red blood cells from breaking down and blood clots from forming. Ultomiris is a type of monoclonal antibody. Also called ravulizumab.",
"synonyms": [
"ravulizumab"
],
"references": [
"NCI Dictionary of Cancer Terms"
],
"url": "https://mlchart.com/terminology/oncology/ultomiris/"
}
Record 16,900 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.